Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan

被引：0
|
作者：
Yugo Chisaki
Yoshiki Kuwada
Chikako Matsumura
Yoshitaka Yano
机构：
[1] Kyoto Pharmaceutical University,Education and Research Center for Clinical Pharmacy
来源：
Clinical Drug Investigation | 2021年 / 41卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：381 / 389
页数：8
相关论文
共 50 条
  • [1] Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan
    Chisaki, Yugo
    Kuwada, Yoshiki
    Matsumura, Chikako
    Yano, Yoshitaka
    CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 381 - 389
  • [2] Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer
    Li, Jiahao
    Zhang, Tiantian
    Lu, Peiyao
    Zhao, Jianfu
    Chen, Lin
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (10) : 705 - 713
  • [3] Cost-effectiveness of combined atezolizumab/nab-paclitaxel for advanced triple-negative breast cancer.
    Salans, Mia A.
    Cherry, Daniel R.
    Yip, Anthony T.
    Courtney, Patrick T.
    Kumar, Abhishek
    Murphy, James Don
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer A Cost-Effectiveness Analysis
    Weng, Xiuhua
    Huang, Xiaoting
    Li, Hongchao
    Lin, Shen
    Rao, Xin
    Guo, Xianzhong
    Huang, Pinfang
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (05): : 340 - 348
  • [5] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    O'Sullivan, Hazel
    Collins, Dearbhaile
    O'Reilly, Seamus
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 986 - 986
  • [6] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    Schmid, P.
    Adams, S.
    Rugo, H. S.
    Schneeweiss, A.
    Barrios, C. H.
    Iwata, H.
    Dieras, V.
    Hegg, R.
    Im, S. -A.
    Wright, G. Shaw
    Henschel, V.
    Molinero, L.
    Chui, S. Y.
    Funke, R.
    Husain, A.
    Winer, E. P.
    Loi, S.
    Emens, L. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22): : 2108 - 2121
  • [7] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer REPLY
    Schmid, Peter
    Chui, Stephen Y.
    Emens, Leisha A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 987 - 988
  • [8] PHARMACOECONOMIC ANALYSIS OF ATEZOLIZUMAB PLUS NAB-PACLITAXEL IN THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
    Kolbin, A.
    Velum, I
    Balykina, Y.
    Proskurin, M.
    VALUE IN HEALTH, 2019, 22 : S510 - S510
  • [9] PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer
    Rugo, Hope S.
    Loi, Sherene
    Adams, Sylvia
    Schmid, Peter
    Schneeweiss, Andreas
    Barrios, Carlos H.
    Iwata, Hiroji
    Dieras, Veronique
    Winer, Eric P.
    Kockx, Mark M.
    Peeters, Dieter
    Chui, Stephen Y.
    Lin, Jennifer C.
    Duc, Anh Nguyen
    Viale, Giuseppe
    Molinero, Luciana
    Emens, Leisha A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (12): : 1733 - 1743
  • [10] Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
    Kang, Connie
    Syed, Yahiya Y.
    DRUGS, 2020, 80 (06) : 601 - 607
12345